Document is current

Article History

Accepted: 24 April 2023

First Online: 15 May 2023

Competing interests

: S.I.I. serves as an adviser and consultant to AstraZeneca. L.G. has received research funding (via her institution) from Adaptimmune, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Genentech, Incyte, Leap Therapeutics, Loxo Oncology, Macrogenics, Merck, Novartis, Nucana, QED Therapeutics, Relay Therapeutics, Servier and Taiho Oncology, and serves as an adviser or consultant to Alentis Therapeutics, AstraZeneca, Black Diamond, Exelixis, Genentech, H3Biomedicine, Incyte, QED Therapeutics, Servier, Sirtex Medical, Taiho Oncology and Transthera Bio. A.L. declares travel and educational support from Advanced Accelerator Applications, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and SirtEx; speaker’s honoraria from Advanced Accelerator Applications, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED Therapeutics and Servier; and advisory or consultancy roles with Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GENFIT, Ipsen, Nutricia, QED Therapeutics, Roche, Servier and TransThera Biosciences; and is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. G.S. has received grant support from Roche, and declares consultancy roles with AstraZeneca, Chiesi, Evidera, Integra, Novartis and Roche. S.A., J.D.Y. and G.J.G. declare no competing interests.